Recombinant Human VEGF121 Instruction

General description

Vascular Endothelial Growth Factor 121 is a freely diffusible splice isoform of VEGF-A that lacks the heparin-binding domain, enabling unrestricted tissue distribution and systemic activity. It retains full VEGFR2 binding and angiogenic potency while exhibiting distinct pharmacokinetic properties. Recombinant Human VEGF121 Protein (Y12301) is expressed from mammalian cells. It contains AA Ala 27 - Arg 147 (Accession # P15692), and is widely used in advanced cell culture, vascular biology, and therapeutic angiogenesis research.

Application

· Systemic Angiogenesis Studies — Models VEGF distribution and activity in tissues with limited heparan sulfate.

· Endothelial Cell Survival and Proliferation — Supports growth and maintenance of vascular endothelial cultures.

· Ischemic Tissue Revascularization Research — Investigates therapeutic angiogenesis in myocardial and peripheral ischemia models.

· Vascular Permeability and Edema Studies — Examines VEGF-induced vascular leakage without matrix sequestration.

· Serum-Free Culture Systems — Suitable for chemically defined and xeno-free cell culture media.

Product Specifications

Stability and Reconstitution

· 36 months at -20°C to -80°C in lyophilized state;

· 6 months at -20°C to -80°C under sterile conditions after reconstitution;

· 7-10 days at 2°C to 8°C under sterile conditions after reconstitution;

· Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

· It is recommended to redissolve in 4mM HCL.

Backgroud

Vascular Endothelial Growth Factor 121, also known as VEGF121, is the shortest diffusible splice variant of the VEGF-A gene, lacking the heparin-binding domain encoded by exon 7 present in VEGF165 and longer isoforms. This structural difference results in markedly distinct biological behavior: VEGF121 does not bind heparan sulfate proteoglycans and therefore diffuses freely through tissues and biological fluids without matrix sequestration. While VEGF165 creates localized angiogenic gradients through heparin-mediated retention, VEGF121 distributes systemically and activates endothelial cells distant from the source. Both isoforms bind VEGFR2 with similar affinity and induce comparable endothelial cell proliferation, migration, and survival responses. However, VEGF121 does not bind neuropilin-1, potentially altering signaling kinetics and downstream transcriptional outputs. In research applications, VEGF121 is particularly valuable for studying the role of heparin binding in VEGF tissue localization, modeling systemic versus localized angiogenic responses, and investigating therapeutic angiogenesis strategies where widespread vascular stimulation is desired. VEGF121 is also useful for endothelial cell culture applications where matrix-bound VEGF165 may create localized signaling artifacts, and for vascular permeability studies where free diffusion is required to model edema formation accurately.

Q&A

Q1: What is VEGF121 mainly used for?

VEGF121 is primarily used for systemic angiogenesis studies, endothelial cell culture, ischemic revascularization research, and vascular permeability studies.

Q2: Is this VEGF121 suitable for serum-free culture systems?

Yes. EastMabBio recombinant VEGF121 is compatible with serum-free, xeno-free, and chemically defined media systems.

Q3: How should recombinant VEGF121 be stored?

Lyophilized protein should be stored at -20°C or below. After reconstitution, aliquot and avoid repeated freeze-thaw cycles.

Q4: What shipping conditions are used?

Products are shipped on dry ice with validated cold-chain packaging to maintain stability during international transportation.

Q5: Do you provide QC documents?

Yes. COA, MSDS, TSE-BSE statements, endotoxin reports, bioactivity data, and additional QC documentation are available upon request.